Turn Therapeutics Inc. (TTRX)
NASDAQ: TTRX · Real-Time Price · USD
9.12
+0.09 (1.00%)
At close: Jul 17, 2026, 4:00 PM EDT
9.00
-0.12 (-1.32%)
After-hours: Jul 17, 2026, 7:31 PM EDT
Turn Therapeutics Employees
Turn Therapeutics had 2 employees as of December 31, 2025. The number of employees decreased by 2 or -50.00% compared to the previous year.
Employees
2
Change
-2
Growth
-50.00%
Revenue / Employee
n/a
Profits / Employee
-$1,918,253
Market Cap
271.67M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 2 | - | - | 2 | 0 |
| Jun 30, 2025 | 2 | -2 | -50.00% | 2 | 0 |
| Jun 30, 2024 | 4 | - | - | 1 | 3 |
| Dec 31, 2023 | 4 | - | - | 1 | 3 |
Related Stocks
| Company Name | Employees |
|---|---|
| MacroGenics | 293 |
| Niagen Bioscience | 117 |
| SAB Biotherapeutics | 86 |
| Lineage Cell Therapeutics | 77 |
| InflaRx | 65 |
| ALX Oncology Holdings | 43 |
| Sol-Gel Technologies | 28 |
| Opus Genetics | 28 |
TTRX News
- 10 days ago - Turn Therapeutics Transcript: Study update - Transcripts
- 10 days ago - Turn Therapeutics Press release: Study update - Filings
- 10 days ago - Turn Therapeutics Slides: Study update - Filings
- 10 days ago - Turn Therapeutics announces final Stage 2 design of atopic dermatitis program - TheFly
- 10 days ago - Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis - Business Wire
- 11 days ago - Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Business Wire
- 6 weeks ago - Turn Therapeutics Transcript: Jefferies Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Turn announces interim analysis findings from Phase 2 trial of GX-03 - TheFly